3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Triple Negative Breast Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Breast Neoplasms
2
Bile Duct Neoplasms
2
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
SCLC
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Non Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Lung Diseases
1
High Grade Serous Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Fallopian Tube Neoplasms
1
Extensive Stage Small Cell Lung Cancer
1
Cholangiocarcinoma
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
Carboplatin
6
durvalumab
4
Paclitaxel
3
atezolizumab
2
sotorasib
1
necitumumab
1
ceralasertib
1
cemiplimab
1
alectinib
1
Radiotherapy
1
Radiosurgery
1
Pemetrexed
1
Gemcitabine
1
Etoposide
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Respiratory Tract Neoplasms
×
ceralasertib
×
Clear all
NCT05941897
2026-03-05
LOTOS
AstraZeneca
Phase 2
Active not recruiting
39 enrolled